POCT Market in Japan: Key Research Findings 2020
Yano Research Institute (the President, Takashi Mizukoshi) carried out a survey on the domestic POCT (point-of-care testing) market and found out the market size, the trend of market players, and future perspectives.
The domestic POCT (point-of-care testing) market size (i.e., the total sales of 9 major testing categories at the businesses) declined by 0.6% to end up with 108,800 million yen in FY2019. Although overall POCT products showed relatively stable sales, the infection of influenza virus ended by February 2020 replaced by the COVID-19 pandemic, which led people to avoid the act of inspecting influenza virus. This significantly reduced the sales of influenza rapid test kit from the previous fiscal year, causing the entire POCT product market size to decline slightly.
New Moves in Blood Coagulation Measuring Instrument
In the blood coagulation measurement category, small PT-INR (Prothrombin Time-International Normalized Ratio) machines for quick measuring of PT and INR levels used to be the major instrument for monitoring the patients on anticoagulant (warfarin) treatment. As direct oral anticoagulant therapy becoming popular, the market of inspections for the warfarin-treatment patients seems to have passed the peak.
On the other hand, those POCT products drawing attention are ACT (activated clotting time) measuring device for monitoring optimum dose of anticoagulant (heparin, etc.) at the time when extracorporeal circulation system is used for surgical operations, and comprehensive blood coagulability measuring instrument employed for hemostasis management at the time of mass bleeding.
As the COVID-19 infections expanded in 2020, the measures to prevent infections such as wearing masks and washing hands have become thoroughly taken, which is affecting the peripheral POCT market. While FY2019 saw decline in demand for influenza rapid test kits, further decreased demand may be observed for the rapid test kits for various infectious diseases in FY2020.
On the other hand, rapid antigen test kits for COVID-19 were released in 2020 as an extracorporeal diagnostic drug. Although accuracy of testing is inferior to PCR testing, it has attracted attention for whether or not the kits with the ability to quickly judge positive or negative decisions will be demanded. Also, regarding COVID-19, in addition to rapid genetic testing, there have been some systems developed, enabling simultaneous detection of multiple infectious genes including those of influenza, which are expected to be established as a new category of POCT.
The copyright and all other rights pertaining to this report belong to Yano Research Institute.
Please contact our PR team when quoting the report contents for the purpose other than media coverage.
Depending on the purpose of using our report, we may ask you to present your sentences for confirmation beforehand.